The Clinical Research E-News

Volume 3: ISSUE 2: January 26, 2011

Now Open:
E2208, Randomized Phase II Study of Paclitaxel With or Without the Anti-IGF-IR mAb Cixutumumab (IMC-A12) as Second Line Treatment for Patients With Metastatic Esophageal or GE Junction Cancer

E1608, A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients with Advanced Melanoma

Coming soon:
CALGB 90802, Randomized Phase III trial comparing everolimus plus placebo versus everolimus plus bevacizumab for advanced renal cell carcinoma progressing after treatment with tyrosine kinase inhibitors

E2408, A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma

E3108, A Phase II Prospective Trial Correlating Progression Free Survival with CYP2D6 Activity in Patients with Metastatic Breast Cancer Treated with Single Agent Tamoxifen.

E7208, A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy.
NSABP C-11, A Phase III Study Evaluating the Role of Preoperative Chemotherapy and Bevacizumab in Patients with Potentially Resectable Hepatic Colorectal Metastases

RTOG 0631, Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis

RTOG 0839, Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer

RTOG0912, A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib/Placebo, for the Treatment of Anaplastic Thyroid Cancer

RTOG 1008, A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors

RTOG 1010, A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma

If your site is interested in participating in any of these studies please contact Rolma Gano at 215-955-7954 or Rolma.gano@jeffersonhospital.org.
Regulatory Update:
E1508, Addendum #5
E1697, Closure Letter
E4508, Addendums #5-6
R0534
R0539

No Re-consents are mandated for any of the above studies.

Please contact Rolma Gano with any repository or other regulatory related questions.

CTSU Update:
Please contact Joshua Schoppe with any CTSU related issues at 215-955-0448 or Joshua.Schoppe@jeffersonhospital.org

ECOG Update:
ECOG will no longer mail hard copies of the protocol mailing item list or any protocol documents to sites in conjunction with the bi-monthly protocol mailing. Moving forward, all protocols and related documents, including the mailing item list, will be accessed via group-wide e-mail notification and the ECOG webpage (www.ecog.org). If you are currently not receiving notifications via e-mail from ECOG or need access to the webpage, please contact the Coordinating Center at ecog.membership@jimmy.harvard.edu.

If you have an ECOG related question please contact Joshua Schoppe.

NSABP Update:
NSABP group meeting is March 24-27, 2011 in Boca Raton, FL. Go to the following link for meeting information and registration.
http://www.meetingsinfo.com/hotelinformation/Boca_Raton/home.html
If you have an NSABP related question please contact Vicki Squire at 
vicki.squire@jeffersonhospital.org or at 215-503-5641.

**RTOG Update:**
**RTOG 0529:** IMRT Less Toxic, as Effective as Conventional Radiation Therapy against Anal. Combining chemotherapy with intensity-modulated radiation therapy (IMRT) is just as effective after two years in treating anal cancer as chemotherapy and conventionally delivered radiation therapy, but with fewer significant side effects according to new research presented by RTOG. The results of an RTOG phase II trial were presented at the eighth annual American Society for Clinical Oncology. To read more go to: [http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=103&abstractID=71101](http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=103&abstractID=71101)

Please contact Joshua Schoppe or Vicki Squire with any RTOG related issues.

**Jefferson Oncology Group (JOG) Update:**
If your site has any JOG inquiries please contact either Joshua Schoppe or Vicki Squire.

**Jefferson Kimmel Cancer Center Network Homepage:**

**Upcoming Events:**
**CRA Quarterly Meeting**, Philadelphia, PA: March 16th (Change in Date)
**NSABP Semiannual Meeting**, Boca Raton, FL: March 24-27
**JKCCN All Day Annual Scientific and Clinical Symposium Topic: Breast Cancer**, Philadelphia, PA: April 8th
**ECOG Semiannual Meeting**, Boston, MA: June 10-12
The Clinical Research E-News Archive is now located on the Kimmel Cancer Center webpage under the JKCCN Member Area: http://www.kimmelcancercenter.org/jkccn/e-newsletters.html

Please provide feedback and any suggestions to Joshua Schoppe at 215-955-0448 or email Joshua.schoppe@jeffersonhospital.org